Nonculprit Lesion Complexity and Timing of Complete Revascularization in Patients Presenting With Acute Coronary Syndrome and Multivessel Disease: Insights From the BIOVASC Trial

BACKGROUND: The optimal timing of complete revascularization for patients with acute coronary syndrome, multivessel disease and complex nonculprit coronary lesions (NCL) remains unclear. METHODS: The BIOVASC trial randomized patients with acute coronary syndrome and multivessel disease to immediate complete revascularization and staged complete revascularization. The primary end point was a composite of all-cause mortality, myocardial infarction, unplanned ischemia-driven revascularization, or cerebrovascular events at 2-year follow-up. In this exploratory post hoc analysis, patients were classified as having complex NCL if at least 1 nonculprit lesion met the following criteria: true bifurcation; severe calcification; lesion length >20 mm; aorto-ostial lesion; left main lesion. We aimed to compare a strategy of immediate complete revascularization and staged complete revascularization in patients presenting with acute coronary syndrome and multivessel disease with complex NCL. Moreover, we sought to compare patients with complex and noncomplex NCLs in terms of clinical outcomes. RESULTS: Among the 1525 patients enrolled in the BIOVASC trial, 550 (36.1%) had a complex NCL. The presence of a complex NCL was associated with a significantly higher incidence of the primary end point compared with noncomplex NCL (adjusted hazard ratio, 1.49 [95% CI, 1.11–2.02]; P =0.01), including spontaneous myocardial infarction (adjusted hazard ratio, 1.86 [95% CI, 1.12–3.09]; P =0.02). In patients with complex NCL, the cumulative incidence of the primary end point was 15.7% in the immediate complete revascularization group and 17.5% in the staged complete revascularization group (hazard ratio, 0.86 [95% CI, 0.57–1.31]; P =0.49). No significant interaction was observed between the presence of a complex NCL and revascularization strategy for the primary end point ( P for interaction=0.40). CONCLUSIONS: In patients with acute coronary syndrome and multivessel disease, patients with complex NCL experienced worse clinical outcomes at 2-year follow-up, driven by higher rates of myocardial infarction. However, no statistically significant interaction was observed between NCL complexity and the effect of immediate complete revascularization versus staged complete revascularization. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03621501.

Authors

Institutions

Publication Details

Journal
Circulation Cardiovascular Interventions
Published
2026-11-13
DOI
https://doi.org/10.1161/circinterventions.126.017520
Primary Topic
Coronary Interventions and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Nonculprit Lesion Complexity and Timing of Complete Revascularization in Patients Presenting With Acute Coronary Syndrome and Multivessel Disease: Insights From the BIOVASC Trial

Nicolas M. Van Mieghem, Wijnand K. den Dekker, Jacob J. Elscot, Manel Sabaté et al.
1 links
Circulation Cardiovascular Interventions
Coronary Interventions and Diagnostics
article

Nonculprit Lesion Complexity and Timing of Complete Revascularization in Patients Presenting With Acute Coronary Syndrome and Multivessel Disease: Insights From the BIOVASC Trial

Nicolas M. Van Mieghem, Wijnand K. den Dekker, Jacob J. Elscot, Manel Sabaté, Roberto Diletti, Johan Bennett, Gianmaria Scherillo, Giovanni Esposito, Eric H. Boersma
article en

Abstract

BACKGROUND: The optimal timing of complete revascularization for patients with acute coronary syndrome, multivessel disease and complex nonculprit coronary lesions (NCL) remains unclear. METHODS: The BIOVASC trial randomized patients with acute coronary syndrome and multivessel disease to immediate complete revascularization and staged complete revascularization. The primary end point was a composite of all-cause mortality, myocardial infarction, unplanned ischemia-driven revascularization, or cerebrovascular events at 2-year follow-up. In this exploratory post hoc analysis, patients were classified as having complex NCL if at least 1 nonculprit lesion met the following criteria: true bifurcation; severe calcification; lesion length >20 mm; aorto-ostial lesion; left main lesion. We aimed to compare a strategy of immediate complete revascularization and staged complete revascularization in patients presenting with acute coronary syndrome and multivessel disease with complex NCL. Moreover, we sought to compare patients with complex and noncomplex NCLs in terms of clinical outcomes. RESULTS: Among the 1525 patients enrolled in the BIOVASC trial, 550 (36.1%) had a complex NCL. The presence of a complex NCL was associated with a significantly higher incidence of the primary end point compared with noncomplex NCL (adjusted hazard ratio, 1.49 [95% CI, 1.11–2.02]; P =0.01), including spontaneous myocardial infarction (adjusted hazard ratio, 1.86 [95% CI, 1.12–3.09]; P =0.02). In patients with complex NCL, the cumulative incidence of the primary end point was 15.7% in the immediate complete revascularization group and 17.5% in the staged complete revascularization group (hazard ratio, 0.86 [95% CI, 0.57–1.31]; P =0.49). No significant interaction was observed between the presence of a complex NCL and revascularization strategy for the primary end point ( P for interaction=0.40). CONCLUSIONS: In patients with acute coronary syndrome and multivessel disease, patients with complex NCL experienced worse clinical outcomes at 2-year follow-up, driven by higher rates of myocardial infarction. However, no statistically significant interaction was observed between NCL complexity and the effect of immediate complete revascularization versus staged complete revascularization. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03621501.

Circulation Cardiovascular Interventions
Universitair Ziekenhuis Leuven (BE), Erasmus MC (NL), Hospital Clínic de Barcelona (ES), Federico II University Hospital (IT), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Erasmus MC Hart en Vaat Instituut (NL), University of Naples Federico II (IT), Universitat de Barcelona (ES)
Good health and well-being
Coronary Interventions and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon